2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)

ESC Scientific Document Group, Alexander R. Lyon, Teresa López-Fernández, Liam S. Couch, Riccardo Asteggiano, Marianne C. Aznar, Jutta Bergler-Klein, Giuseppe Boriani, Daniela Cardinale, Raul Cordoba, Bernard Cosyns, David J. Cutter, Evandro de Azambuja, Rudolf A. de Boer, Susan F. Dent, Dimitrios Farmakis, Sofie A. Gevaert, Diana A. Gorog, Joerg Herrmann, Daniel LenihanJavid Moslehi, Brenda Moura, Sonja S. Salinger, Richard Stephens, Thomas M. Suter, Sebastian Szmit, Juan Tamargo, Paaladinesh Thavendiranathan, Carlo G. Tocchetti, Peter van der Meer, Helena J.H. van der Pal, Patrizio Lancellotti, Franck Thuny, Magdy Abdelhamid, Victor Aboyans, Berthe Aleman, Joachim Alexandre, Ana Barac, Michael A. Borger, Ruben Casado-Arroyo, Jennifer Cautela, Jolanta Čelutkienė, Maja Cikes, Alain Cohen-Solal, Kreena Dhiman, Stéphane Ederhy, Thor Edvardsen, Laurent Fauchier, Michael Fradley, Julia Grapsa, Sigrun Halvorsen

Research output: Contribution to journalArticlepeer-review

45 Citations (Scopus)
Original languageEnglish
Pages (from-to)4229-4361
Number of pages133
JournalEuropean Heart Journal
Volume43
Issue number41
Early online date26 Aug 2022
DOIs
Publication statusPublished - 1 Nov 2022

Keywords

  • Amyloid light-chain cardiac amyloidosis
  • Androgen deprivation therapy
  • Anthracycline
  • Arrhythmias
  • Atrial fibrillation
  • Biomarkers
  • Cancer
  • Cancer survivors
  • Carcinoid syndrome
  • Cardiac magnetic resonance
  • Cardiac tumour
  • Cardio-oncology
  • Cardiotoxicity
  • Chemotherapy
  • Coronary artery disease
  • Echocardiography
  • Fluoropyrimidine
  • Guidelines
  • Haematopoietic stem cell transplantation
  • Heart failure
  • Hormone therapy
  • Hypertension
  • Immunotherapy
  • Ischaemic heart disease
  • Myocarditis
  • Pericardial disease
  • Proteasome inhibitors
  • Pulmonary hypertension
  • QTc prolongation
  • Radiotherapy
  • Risk stratification
  • Strain
  • Thrombosis
  • Trastuzumab
  • Valvular heart disease
  • Vascular endothelial growth factor inhibitors (VEGFi)
  • Venous thromboembolism

Cite this